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Abstract
Introduction: The universal test and treat strategy (UTT) was developed to maximize the proportion of all HIV-positive indi-
viduals on antiretroviral treatment (ART) and virally suppressed, assuming that it will lead to a reduction in HIV incidence at
the population level. The evolution over time of the cross-sectional HIV care cascade is determined by individual longitudinal
trajectories through the HIV care continuum and underlying population dynamics. The purpose of this paper is to quantify the
contribution of each component of population change (in- and out-migration, HIV seroconversion, ageing into the cohort and
definitive exit such as death) on the HIV care cascade in the context of the ANRS 12249 Treatment as Prevention (TasP) cluster-
randomized trial, investigating UTT in rural KwaZulu-Natal, South Africa, between 2012 and 2016.
Methods: HIV test results and information on clinic visits, ART prescriptions, viral load and CD4 count, migration and deaths
were used to calculate residency status, HIV status and HIV care status for each individual on a daily basis. Position within
the HIV care continuum was considered as a score ranging from 0 (undiagnosed) to 4 (virally suppressed). We compared the
cascade score of each individual joining or leaving the population of resident adults living with HIV with the average score of
their cluster at the time of entry or exit. Then, we computed the contribution of each entry or exit on the average cascade
score and their annualized total contribution, by component of change.
Results: While the average cascade score increased over time in all clusters, that increase was constrained by population
dynamics. Permanent exits and ageing into the people living with HIV cohort had a marginal effect. Both in-migrants and out-
migrants were less likely to be retained at each step of the HIV care continuum. However, their overall impact on the cross-
sectional cascade was limited as the effect of in- and out-migration balanced each other. The contribution of HIV seroconver-
sions was negative in all clusters.
Conclusions: In a context of high HIV incidence, the continuous flow of newly infected individuals slows down the efforts to
increase ART coverage and population viral suppression, ultimately attenuating any population-level impact on HIV incidence.
Clinical Trial Number: NCT01509508 (clinicalTrials.gov)/DOH-27-0512-3974 (South African National Clinical Trials Register).
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1 | INTRODUCTION
Early antiretroviral treatment (ART) of HIV-positive patients
has been shown to prevent transmission of HIV [1], in addi-
tion to individual benefits in terms of reducing morbidity and
mortality [2,3]. The universal test and treat (UTT) strategy
was developed by extending this idea to the population level
under the hypothesis that HIV testing of all adult members of
a community, followed by immediate ART initiation of nearly
all HIV-positive individuals, regardless of immunological or
clinical staging, will prevent onward transmission and reduce
HIV incidence in the community. This strategy is supported by
modelling work suggesting that such an approach, if success-
fully implemented, could eliminate HIV transmission in South
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Africa [4], and in a large population-based cohort from rural
KwaZulu-Natal, South Africa, demonstrating a strong inverse
association between ART coverage and HIV acquisition [5].
The implementation of any UTT strategy involves improving
all steps of the “cascade of HIV care” [6,7], as set out by
UNAIDS in their 90-90-90 targets to be reached by 2020,
that is 90% of all people living with HIV (PLWHIV) being diag-
nosed, 90% of those being in care and receiving ART and 90%
of those on ART with viral suppression [8]. This type of HIV
care cascade is measured by a population-based and cross-
sectional set of indicators estimating the proportion of
HIV-positive individuals diagnosed, in care, on ART and virally
suppressed among all PLWHIV residing within a certain geo-
graphical area at a specific time point, although alternative
longitudinal measurements of the cascade exist [9].
The evolution over time of a cross-sectional HIV care cas-
cade is determined by two elements: (i) the journey of HIV-
positive individuals through the care continuum (longitudinal
care trajectories), and (ii) the changes in the underlying popu-
lation of resident PLWHIV (population dynamics, i.e. in- and
out-migration, HIV seroconversion, ageing into the cohort and
definitive exit such as death).
Migration is one component of population dynamics. It has
been shown in rural South Africa that even relatively short-
distance migration events confer substantial additional risk of
HIV acquisition [10]. More generally, mobility is associated
with increased risk of ART non-adherence, lost to follow-up,
deterioration in CD4 count, HIV-related death, development
of drug resistance and general non-continuity of HIV care
[11].
Beyond the understanding of individual trajectories through
the HIV care continuum (sometimes referred as longitudinal
cascade [12]), it is also important to quantify the structural
effect of the dynamics of the PLWHIV population and its
impact on the cross-sectional HIV care cascade.
The ANRS 12249 Treatment as Prevention (TasP) trial
implemented a UTT strategy in rural KwaZulu-Natal to test
the impact of universal ART on population HIV incidence. The
objectives of this analysis are: (i) to document the dynamics of
the PLWHIV population in the trial area over time, distinguish-
ing the different components of population change; (ii) to iden-
tify the position within the HIV care continuum of individuals
joining or leaving the PLWHIV population at the time of entry
or exit; (iii) to compare their care position with the average
care position of the local PLWHIV population; and finally, (iv)
to quantify the contribution of each component of population
change on the cross-sectional HIV care cascade.
2 | METHODS
2.1 | Study setting and design
The TasP trial was a phased two-arm cluster-randomized trial
implemented by the Africa Health Research Institute (AHRI)
in Hlabisa sub-district, northeast KwaZulu-Natal, South Africa,
in a rural area with approximately 28,000 isiZulu-speaking res-
ident adults. Adult HIV prevalence in the sub-district was
around 30% [13,14]. Hlabisa sub-district is characterized by
frequent migration [15,16], low marital rates and late marriage
[17]. On average, one adult in ten in the trial area is employed
[18].
The trial aimed to investigate whether immediate ART initi-
ation offered to all HIV-positive individuals, identified through
home-based HIV testing will reduce HIV incidence in the area.
Trial protocol and study procedures have previously been
reported in detail [19,20].
The trial was implemented from March 2012 to June 2016
using a phased approach: four clusters opened in 2012, six
additional clusters opened in 2013 and 12 in 2014. All 22
clusters (2 9 11) were followed until mid-2016. Each cluster
was designed to correspond to an average of about 1,000 res-
ident adults.
The UTT strategy tested in TasP trial had two main compo-
nents: (i) repeat home-based HIV testing (both arms) and (ii)
immediate ART initiation (intervention arm).
In both trial arms, HIV counsellors visited all local house-
holds and enumerated, with the household head or another
adult household member, all resident adult (16 years and
above) household members (initial census during the first sur-
vey round). Residency was defined in trial protocol as spend-
ing at least four nights per week within the homestead
(de jure household members at the survey date). At each sub-
sequent home-based survey round, conducted six-monthly,
newly identified households and all previously registered
households were (re)visited and the list of resident adult
household members was updated. Exits (including deaths and
out-migration from trial area) were documented as reported
from another household member.
Eligible individuals providing written informed consent in isi-
Zulu responded to a socio-demographic and sexual behaviour
questionnaire and gave a finger prick sample collected as a
dried blood spot (DBS), used for HIV incidence estimation.
HIV counsellors also offered individuals point-of-care rapid
HIV counselling and testing. Participants identified HIV-posi-
tive through DBS but who refused HIV rapid test at a specific
survey round were not notified of their DBS result. However,
they were re-invited to test for HIV in a subsequent survey
round. All trial participants identified as HIV positive (through
rapid HIV test or self-report) were referred to a local trial
clinic set up by the trial and situated in the trial cluster in
which they lived, located at less than 45 minutes walking dis-
tance. From May 2013, support for linkage to trial clinics
through phone calls and home visits by a dedicated trial team
was offered to individuals not linked to care within
three months after referral.
In the trial clinics of the control clusters, HIV-positive adults
were offered ART according to national guidelines (initially
CD4 count ≤350/lL, then ≤500/lL from January 2015). In
the trial clinics of the intervention clusters, all HIV-positive
adults were offered the opportunity to begin ART immediately
regardless of CD4 count or clinical staging. The trial area was
also served by three local governmental primary care clinics
of the department of health providing HIV testing, HIV care
and ART according to national guidelines only [21]. HIV-posi-
tive participants of both arms could opt to receive HIV care in
primary care clinics or transfer to a trial clinic.
The Biomedical Research Ethics Committee (BREC), Univer-
sity of KwaZulu-Natal, South Africa (BFC 104/11) and the
Medicines Control Council of South Africa approved the trial.
The trial was also registered on ClinicalTrials.gov:
NCT01509508 and South African National Clinical Trials
Register: DOH-27-0512-3974.
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2.2 | Sources of data
The main data source for this analysis was the trial database,
which provided information on trial registrations and trial
exits; uptake and results of home-based rapid HIV testing;
third generation ELISA HIV serological results from DBS; and
clinic visits, ART prescription and viral loads of PLWHIV seen
in trial clinics.
Two additional data sources were used to capture informa-
tion from PLWHIV seen in local governmental clinics: (a) viral
loads and CD4 counts from National Health Laboratory Ser-
vice (NHLS); and (b) ART clinic visits and ART prescriptions
from the AHRI clinical database (ACCDB) which is managed
by the Hlabisa Department of Health and AHRI. Both NHLS
and the ACCDB database contain data from Hlabisa primary
care clinics since 2004 [21]. Linkage between trial, NHLS and
ACCDB database used a probabilistic score based on first
name, last name, date of birth, South African ID number and
cell phone number. Matching of the databases was approved
by the BREC in March 2013 (Protocol Amendment 4).
2.3 | Daily statuses
Residency, HIV status and HIV care status (if resident and
HIV-positive) were estimated daily for all individuals regis-
tered within the trial.
Out-migration and permanent exits were documented
through trial exits. In-migration and ageing into the cohort (16th
birthdays) were derived from the resident household members
lists updated at every round. Dates of in-migration events were
randomly imputed using a random point approach (uniform dis-
tribution) between the last home visit where individuals were
known as non-resident and the first home visit where they were
considered as resident. An individual could contribute several
migration events, for example if he/she out-migrated from the
trial area and re-entered the trial area at a later date.
HIV status was identified using multiple sources: repeat
DBS, repeat rapid tests, HIV-positive self-reports and HIV
clinic visits in trial and/or local governmental clinics, providing
information on HIV status at specific dates. A case-by-case
investigation (including additional laboratory analysis) was per-
formed to solve any inconsistent data. An individual was con-
sidered as HIV-negative before the last known negative status
and as HIV-positive after the first known positive status. For
those in whom a negative status was followed by a positive
one, date of seroconversion was imputed using a random
point approach (uniform distribution). For individuals entering
the trial cohort, the first opportunity for the trial team to
ascertain their HIV status occurred de facto after their entry.
For some, a previous record was found in NHLS and/or in
ACCDB database. For the others, we imputed if and when a
potential unobserved HIV seroconversion occurred using the
observed incidence within the same cluster and for people of
the same sex. A similar approach was used to impute a possi-
ble seroconversion before the end of trial follow-up for those
whose last observed HIV status was negative, assuming they
remained undiagnosed until the end of trial follow-up. Individ-
uals with no observed HIV status (i.e. with no data on HIV
status) were excluded from the analysis.
HIV care statuses were defined as: (i) undiagnosed; (ii) diag-
nosed but not actively in care (i.e. never in care or lost to
follow-up); (iii) actively in care but not on ART; (iv) on ART
but not virally suppressed (undocumented viral load or viral
load over 400 copies/lL); and (v) in care, on ART and docu-
mented viral suppression. Position within the HIV care contin-
uum was considered as a score ranging from 0 (undiagnosed)
to 4 (virally suppressed). We note Si,t the score of an individ-
ual i at time t.
An individual was considered as being diagnosed if he/she
had at least one positive rapid test, one self-report as HIV-
positive or had visited a primary care clinic. Date of HIV diag-
nosis was defined as the date of home-based HIV testing for
individuals newly diagnosed by the trial counsellors. For those
already diagnosed when they were interviewed, we consid-
ered the date of the first record in NHLS or ACCDB data-
base, if any. It should be noted that for individuals tested in
primary care clinics, a CD4 count is performed the same day
in case of positive result, resulting in a record in NHLS data-
base. For the few individuals self-reporting being HIV-positive
but with no previous record in NHLS/ACCDB, we considered
as a proxy of the diagnosis date the date of the self-report.
Being actively in HIV care in a trial clinic was defined as not
being >90 days late of a scheduled clinic appointment date
[22] (visits were scheduled monthly if on ART, six-monthly if
not yet eligible for ART in control arm). Due to the nature of
the data available in NHLS and ACCDB database with neither
database being exhaustive (some individuals recorded in one
database were not found in the other, in particular pre-ART
patients not covered by ACCDB), we were not able to use
the same definitions regarding being actively in HIV care in
primary care clinic. For patients matched with ACCDB data-
base, being actively in HIV care was defined as having a clinic
visit recorded in the last four months (one month for next
appointment, this database being limited to ART patients sup-
posed to visit clinics monthly, +3 months late). For patients
matched with NHLS database (which contains only laboratory
test results), it was having a CD4 count or a viral load
recorded in the previous 13 months, CD4 count and viral load
data being considered a proxy for clinic visits, following the
approach proposed by Lessel et al. [23].
Being on ART was defined as having an ART prescription
recorded in the trial or the ACCDB database in the previous
3 months or as having an undetectable viral load (<400
copies/lL) recorded in the last 13 months in the NHLS data-
base, an undetectable viral load being considered here as a
proxy for being on ART for HIV patients recorded in NHLS
database but not found in ACCDB.
Viral suppression was defined as a viral load fewer than 400
copies/lL. The viral load at a given date was estimated by lin-
ear interpolation using all results recorded in the trial and the
NHLS database. The viral load was considered as undocu-
mented before the first available record.
2.4 | Components of population change
We broke down change of the resident PLWHIV population
into five components: (i) ageing into the cohort; (ii) HIV sero-
conversion; (iii) in-migration to the cluster; (iv) out-migration
from the cluster; and (v) permanent exits (deaths or loss of
the ability to provide an informed consent, e.g. due to illness).
Dates of out-migration and permanent exit events were col-
lected by a specific form, while dates of in-migration, ageing
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into the cohort and HIV seroconversion were estimated (see
previous section). A same individual could have experienced
several events over the course of the trial.
2.5 | Statistical analysis
As all clusters were not open at the same time, and have
therefore different observation periods, we performed the
statistical analysis per cluster, from the end of the initial popu-
lation census to the beginning of the last survey round (Fig-
ure 1). In addition, this allows us to see if the impact of
population dynamics on the HIV care cascade is uniform or
heterogenous between clusters.
For a given cluster c, the average cascade score lc,t at time
t is equal to ΣiSi,t/nc,t where nc,t corresponds to the number of
PLWHIV aged 16 years or older, residing within the cluster c
at the date t. This average score is a summary statistic of the
cascade distribution.
We computed, per cluster, rates of each population change
component from the resident HIV-positive population per per-
son years of residency.
To compare the cascade score of a specific individual i joining
or leaving the PLWHIV population with the average score of
their cluster at the time te of entry/exit, we computed di,te as
Si,te  lc,te. We used Student’s t-test to test if the mean of di,te
by type of population movement differed significantly from zero.
The contribution Ce of a specific event e on the change in
the average cascade score at cluster level depends on the
PLWHIV population size and could be defined as di,te/nc,te for
an entry event and di,te/nc,te for an exit event. For a given
cluster c, the sum of all event contributions, that is SCe = Σe
Ce, provides the total contribution of population change on
the average cascade score over time. As all clusters were not
observed for the same amount of time, we annualized these
total contributions for comparing clusters: aSCe = SCe/Tc,
where Tc is the observation period for cluster c.
All analyses were performed using R version 3.4.1 [24].
3 | RESULTS
Overall, 28,419 adults were registered over the course of the
trial. 338 individuals exited the trial area before the end of
the initial census or were registered during the last survey
round. Among the remaining 28,081 individuals: HIV status
was undocumented for 2,582 (9.2%); and 16,994 (60.5%)
remained HIV negative over the analysis period; thus, 8,505
individuals were part of the resident population of PLWHIV
over the analysis period and included in the analysis.
The population HIV care cascade improved over time: the
proportion of PLWHIV in care, on ART and virally suppressed
increased from approximately 30% to 45% to 50%, while the
proportion of PLWHIV not in care (diagnosed or undiagnosed)
decreased from approximately 50% to 35% to 40%, depending
on the duration of trial follow-up in each cluster (Figure 2).
Although the level of the average cascade score differs
between clusters, trends present a similar pattern of increase
in all clusters (Figure 3).
The PLWHIV population is characterized by a high turnover
over the study period: the overall annual exit rate is 22.6%
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Figure 1. Dates of home-based survey rounds activities by clusters, ANRS 12249 TasP trial (2012 to 2016). The light areas in round 1 indi-
cate the time required to complete the initial census of the resident population.
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(2,979 exits for 13,180 person years) and the overall annual
entry rate 22.4% (2,948 entries for 13,180 person years).
Population dynamics were mainly due to out- and in-migration
(annual rate, respectively, of 21.0% and 17.3%). New HIV
infections accounted for a 4.8% annual increase in the
PLWHIV population (625 events: 510 observed seroconver-
sions and eight estimated unobserved seroconversions before
the first observed positive status and 117 after the last nega-
tive one). The annual rate of permanent exits was 1.6% (216
events: 186 deaths and 30 individuals who lost their ability to
consent). Finally, we observed 29 participants already HIV
positive when they reached 16 years of age during the trial.
The distribution of population change by component is similar
between clusters, although the overall net growth is negative
for 14 clusters and positive for the other 8 (Figure 4). Basic
socio-demographic characteristics of PLWHIV entering/exiting
the resident population are provided in supplementary materi-
als (Table S1).
The average cascade score by cluster could be considered
as a good summary statistic of the cross-sectional cascade as
it is highly and significantly (p < 0.0001) correlated (Figure S2)
with the proportions of diagnosed individuals (score ≥ 1), indi-
viduals in care (score ≥ 2), individuals on ART (score ≥ 3), and
individuals virally suppressed (score = 4).
HIV seroconverters, who were undiagnosed at the date of
seroconversion (Figure 5), had a lower cascade score com-
pared to PLWHIV in the same cluster and at the same date
(mean difference: 2.278, p < 0.0001, Figure 6). Half of the
young people turning 16 years old and already infected by
HIV were undiagnosed and only a fifth were on ART at that
time (mean difference: 1.039, p = 0.0007). Permanent exits
had on average a similar score to the rest of PLWHIV in their
4 clusters opened in 2012
6 clusters opened in 2013
12 clusters opened in 2014
January 
 2013
July 
 2013
January 
 2014
July 
 2014
January 
 2015
July 
 2015
January 
 2016
0%
20%
40%
60%
80%
100%
0%
20%
40%
60%
80%
100%
0%
20%
40%
60%
80%
100%
Infected, but
not diagnosed
(score = 0)
Diagnosed, but
not in care
(score = 1)
In care, but
not on ART
(score = 2)
On ART, but not 
virally suppressed
(score = 3)
On ART and 
virally suppressed
(score = 4)
Figure 2. Evolution over time of the population cross-sectional HIV care cascade per group of clusters, ANRS 12249 TasP trial (2012 to
2016).
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cluster (mean difference: 0.030, p = 0.7541), two-thirds being
actively in care at the date of the exit. Most migrants had a
lower position compared to their cluster population, the differ-
ence being higher for in-migrants (mean difference: 0.630,
p < 0.0001) than out-migrants (0.429, p < 0.0001): 26% of
out-migrants were on ART and virally suppressed at the date
they out-migrated compared to 19% among in-migrants at
arrival.
In all clusters (Figure 7), in-migration contributed negatively
to the cluster average cascade score (from 0.210 to 0.043,
median: 0.093) while out-migration contributed positively
(from +0.046 to +0.255, median: +0.108). Because out-
migrants had a lower score compared to local HIV residents,
when they left their cluster, it mechanically increased the
average cascade score of the population left behind. In- and
out-migration compensated each other: the total contribution
of migration was negative in 10 clusters and positive in the
other 12, and close to zero in several clusters (from 0.099
to +0.154, median: +0.002). The contribution of permanent
exits (from 0.019 to +0.032, median: +0.001) and 16th
birthdays (from 0.012 to +0.005, median: 0.004) was mar-
ginal with no clear pattern between clusters. HIV seroconver-
sion had a negative contribution to the cascade in all clusters
(from 0.182 to 0.072, median: 0.117), resulting in a total
contribution of all events being negative almost everywhere
(from 0.190 to +0.032, median: 0.112).
The imputation of potential unobserved HIV seroconver-
sions had a marginal effect. Re-analysing the data without con-
sidering imputed seroconversions (Figure S3) did not change
the results substantively, and the annualized total contribution
of all components on the cluster average score ranged from
0.174 to +0.069 (median: 0.098).
4 | DISCUSSION
Our results demonstrate that the turnover of the PLWHIV
population residing in our trial area was high, more than
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one-fifth being replaced every year. While the average HIV
care cascade score increased over time in all clusters, that
increase was limited due to population dynamics, the total
contribution of all entries and exits being systematically nega-
tive, and it was mainly due to new HIV infections.
In-migrants joined the PLWHIV population at earlier stages
of the cascade and lowered the cluster average score. Even if
out-migrants usually left at a slightly higher position in the
cascade than in-migrants when they arrived, there were also
at earlier stages compared to the rest of the resident popula-
tion. Although this could be counterintuitive, at the population
level, it had a positive effect on the cluster average score. As
a result, out- and in-migration had a balanced impact on the
cross-sectional cascade, both effects cancelling out.
Data collected through the ANRS 12249 TasP trial constitute
a unique opportunity to make a fine description of individual tra-
jectories over time through HIV services, on a daily basis, which
can be done only in very few settings. However, to fully under-
stand our results, it is crucial to understand the limitations of
the data. Due to the nature of available data sources, different
definitions and assumptions were required to estimate individ-
ual statuses. First, in-migration events were not directly col-
lected by TasP fieldworkers and have therefore been derived
by comparison of resident household members lists between
survey rounds. Second, while HIV care statuses were measured
precisely within trial clinics, we had to use proxy indicators
(based on laboratory data in particular) for being in HIV care
and being on ART in local governmental clinics. Measurement of
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Figure 5. Position within the HIV care continuum at the date of entry/exit, by population change component, ANRS 12249 TasP trial (2012
to 2016).
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entry into care is generally robust because a CD4 count and/or
a viral load is almost associated with first clinic visit. However,
the identification of individuals exiting care is delayed for indi-
viduals matched only to NHLS database. In addition, considering
our matching algorithm, the probability that a trial participant
was wrongly associated with a record in ACCDB or NHLS
(type-I error) is relatively small. However, some patients who
resided in the trial area could not be matched (type-II error), for
reasons such as data entry errors or use of different names in
different settings [25]. Third, we did not have any data on indi-
viduals receiving HIV care in the private sector or in primary
care clinics located outside the Hlabisa sub-district, potentially
resulting in an underestimation of population progression
through the HIV care cascade. Our estimates of the proportion
of PLWHIV being in care should be considered as lower bounds.
Finally, 9.5% of trial participants had an undocumented HIV sta-
tus (because the fieldworkers were not able to contact them at
least once or because they systematically refused rapid HIV
tests and to provide a DBS) and were excluded from the analy-
sis. A sensitivity analysis (unpublished yet) suggests that it is not
affecting the observed trends of the population HIV care cas-
cade. However, we could expect higher migration rates and a
higher HIV incidence in that group. Therefore, our estimates of
the contribution of population change on the cascade could thus
be seen as conservative estimates.
The ANRS 12249 TasP trial did not demonstrate a signifi-
cant difference in cumulative incidence by arms [18], due in
particular to a low level of linkage to care [26], resulting in a
limited increase of ART coverage over time and the absence
of differentiation between arms. At the beginning of the trial,
population ART coverage among all HIV-positive adults living
in the study area was estimated at 29.6% in intervention arm
and 33.7% in control arm. ART coverage rose to 53.4%
(+23.8) in the intervention arm and 52.8% (+19.1) in the con-
trol arm by 1 January 2016, with the difference between
arms not statistically significant (p = 0.67) [18].
In our context of high HIV incidence, delays in HIV diagno-
sis is a key barrier to progress through the population HIV
care cascade. Within the ANRS 12249 TasP trial, one-third of
individuals who seroconverted remained undiagnosed after
one year, one-third discovered their HIV-positive status but
did not enter care and one-third linked to an HIV clinic [27].
Overall, with only 17% initiating ART within 12 months after
seroconversion, we are far from the 81% expected by the
model of Granich and colleagues [4] to eliminate HIV trans-
mission in South Africa. The HIV care trajectories were clearly
suboptimal in seroconverters despite the introduction of UTT
services and a trial environment, contributing to a continuous
transmission of HIV within the population.
Migrants in general had a lower position within the contin-
uum of HIV care than the average population: this group
needs specific interventions to link and retain into care over
time. This very mobile population is not living separately from
the rest of the local population. In this rural area with few job
opportunities, people come and go and are still part of local
sexual networks. In this trial, around 40% of participants
reported having a sexual partner located outside of the trial
area, some as far as major cities outside of KwaZulu-Natal
[18]. In this paper, we did not analyse migration patterns and
their associated factors (in particular gender), such topic
needed to be explored further. More generally, the dynamics
between migration, the HIV epidemic and care trajectories
through the health system require additional investigations.
5 | CONCLUSIONS
Migrants face specific vulnerabilities that limit their retention
at each step of the HIV care continuum and coordination to
facilitate continued access to care when people move should
be developed. In a context of high HIV incidence, the continu-
ous flow of newly infected individuals who are less likely to
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Figure 7. Annualized total contribution of population change on cluster average cascade score, by component of population change and per
cluster, ANRS 12249 TasP trial (2012 to 2016). Dotted lines indicate the sum of the total contribution of in- and out-migration. Black lines
indicate the sum of total contribution of all events. Examples of reading: in cluster C01, in-migration events reduced annually the cluster
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per year.
Larmarange J et al. Journal of the International AIDS Society 2018, 21(S4):e25128
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25128/full | https://doi.org/10.1002/jia2.25128
13
link to HIV care and to initiate ART, slows down efforts to
increase overall ART coverage and population viral suppres-
sion, ultimately attenuating any population-level impact on
HIV incidence. Identifying specific interventions to reach
newly infected people as early as possible is a crucial step on
the way towards the end of the epidemic.
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Table S1. Socio-demographic characteristics of individuals who
entered or exited the resident PLWHIV population, by popula-
tion change component, ANRS 12249 TasP trial (2012 to 2016)
Figure S2. Correlation between the average cascade score and
proportions of all resident PLWHIV being diagnosed, in care, on
ART or virally suppressed at cluster level, ANRS 12249 TasP
trial (2012 to 2016)
Figure S3. Sensitive analysis: comparison of annualized total
contribution of population change on cluster average cascade
score, by component of population change and per cluster, with
(A) and without (B) imputation of potential unobserved serocon-
versions.
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